with WHIM syndrome The CXCR4 antagonist plerixafor corrects panleukopenia in patients

[1]  D. McDermott,et al.  AMD3100 is a potent antagonist at CXCR4R334X, a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome , 2011, Journal of cellular and molecular medicine.

[2]  R. Brunauer,et al.  Human Bone Marrow Hosts Polyfunctional Memory CD4+ and CD8+ T Cells with Close Contact to IL-15–Producing Cells , 2011, The Journal of Immunology.

[3]  S. Paul,et al.  Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis. , 2010, Blood.

[4]  Kevin B. Walters,et al.  Live imaging of neutrophil motility in a zebrafish model of WHIM syndrome. , 2010, Blood.

[5]  C. Cunningham-Rundles,et al.  Oligoclonality, impaired class switch and B-cell memory responses in WHIM syndrome. , 2010, Clinical immunology.

[6]  A. Nademanee,et al.  Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization , 2010, Bone Marrow Transplantation.

[7]  A. V. Gulino,et al.  Impaired Recruitment of Grk6 and β-Arrestin2 Causes Delayed Internalization and Desensitization of a WHIM Syndrome-Associated CXCR4 Mutant Receptor , 2009, PloS one.

[8]  A. Nademanee,et al.  Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Andreas Radbruch,et al.  Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow. , 2009, Immunity.

[10]  H. Malech,et al.  WHIM syndrome: congenital immune deficiency disease , 2009, Current opinion in hematology.

[11]  T. Grodzicki,et al.  Familial occurrence of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome , 2008, Archivum Immunologiae et Therapiae Experimentalis.

[12]  N. Naumann,et al.  WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4. , 2007, Blood.

[13]  Alain Dupuy,et al.  WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. , 2005, Blood.

[14]  E. Wherry,et al.  Bone Marrow Is a Preferred Site for Homeostatic Proliferation of Memory CD8 T Cells , 2005, The Journal of Immunology.

[15]  Dominique Schols,et al.  Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection , 2004, Journal of acquired immune deficiency syndromes.

[16]  J. Cyster,et al.  Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5 , 2004, Nature Immunology.

[17]  B. Wood,et al.  Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist. , 2004, Supportive cancer therapy.

[18]  B. Wood,et al.  Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. , 2003, Blood.

[19]  S. Rankin,et al.  Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. , 2003, Immunity.

[20]  R. Gorlin,et al.  Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease , 2003, Nature Genetics.

[21]  T. Fleisher,et al.  Diagnostic paradigm for evaluation of male patients with chronic granulomatous disease, based on the dihydrorhodamine 123 assay. , 2003, The Journal of allergy and clinical immunology.

[22]  Edward J. Fuchs,et al.  Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers , 2000, Antimicrobial Agents and Chemotherapy.

[23]  T. Springer,et al.  The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. , 1999, Immunity.

[24]  R. Bronson,et al.  Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Kouji Matsushima,et al.  The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract , 1998, Nature.

[26]  Masahiko Kuroda,et al.  Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development , 1998, Nature.

[27]  E. Kleinerman,et al.  A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. , 1990, The American journal of medicine.

[28]  C. Krill,et al.  CHRONIC IDIOPATHIC GRANULOCYTOPENIA. , 1964, The New England journal of medicine.

[29]  W. Zuelzer,et al.  "MYELOKATHEXIS"--A NEW FORM OF CHRONIC GRANULOCYTOPENIA. REPORT OF A CASE. , 1964, The New England journal of medicine.